Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast with R-CHOP in High-Risk DLBCL
NCT05796271Phase 1Withdrawn
- Sponsor
- UT Health San Antonio
- Start
- Jan 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of roflumilast in diffuse large B-cell lymphoma (DLBCL), sponsored by UT Health San Antonio. Primary endpoint: Progression-Free Survival at 1 year. Planned start Jan 2024; status: withdrawn.
02
Drugs
roflumilast
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05796271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05796271.